ProQR Therapeutics (PRQR) director discloses share and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ProQR Therapeutics N.V. director Shannon James Samuel filed an initial Form 3 reporting his equity holdings in the company. The filing lists multiple employee share options over ordinary shares with exercise prices ranging from $1.9800 to $15.7800 and expirations between 2026 and 2035, along with directly held ordinary shares.
The Form 3 shows direct ownership of 61,538 ordinary shares of ProQR Therapeutics and a series of vested and time-vested options that continue to vest in quarterly installments, subject to his continuous service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Shannon James Samuel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 33,069 shares (Direct);
Ordinary Shares — 61,538 shares (Direct)
Footnotes (1)
- Fully vested. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
FAQ
What does the ProQR (PRQR) Form 3 filing by Shannon James Samuel report?
The Form 3 reports director Shannon James Samuel’s initial ownership in ProQR. It lists his directly held ordinary shares and multiple employee share options over ordinary shares with specified exercise prices and expiration dates, establishing his starting equity position as an insider.
What types of equity awards are disclosed for Shannon James Samuel in ProQR’s Form 3?
The filing discloses multiple Share Option (Right to Buy) awards over ProQR ordinary shares. Each option series has its own exercise price, expiration date and underlying share amount, reflecting a typical mix of fully vested and time-based vesting schedules.
Do the ProQR (PRQR) Form 3 options held by Shannon James Samuel have long-dated expirations?
Yes. The reported share options carry expiration dates ranging from June 20, 2026 through December 31, 2035. These long-dated options give extended potential for future share acquisition if exercised before their respective expiration dates.